GET DAILY SIGNALSPDS Biotechnology (PDSB): -34% Pullback After a +290% Quarterly Advance
Key Takeaways
- PDSB has declined roughly 34% over the last 30 days, from about $1.52 on October 12 to near $1.00, after a sharp multi-week run higher.
- The pullback follows a speculative rally sparked by a private investment in public equity (PIPE) financing led by Dr. Patrick Soon-Shiong's Nant Capital, announced in early September.
- Despite the recent drop, shares remain up roughly 290% over the trailing quarter, having recovered dramatically from levels below $0.30 in mid-August.
- Heavy equity issuance in the PIPE — approximately 20.9 million shares plus about 20.4 million warrants priced at $0.2825 per unit — has raised dilution concerns that are pressuring sentiment.
- With no approved products or revenue, PDSB is a clinical-stage biotech whose stock remains highly sensitive to clinical, regulatory, and financing headlines.
- For additional context on valuation and catalysts, explore PDSB's Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are approaching this ticker, visit Tickeron's Trending AI Robots section.
PDS Biotechnology (PDSB) Company Overview
PDS Biotechnology Corporation is a clinical-stage immunotherapy company based in Princeton, New Jersey, focused on targeted cancer immunotherapies. Its lead program, PDS0301 (also known as PDS01ADC or NHS-IL12), is an investigational tumor-targeted interleukin-12 immunocytokine meant to concentrate IL-12 in the tumor microenvironment and boost anti-tumor immune response while reducing systemic side effects. The firm also holds the Versamune platform, which includes PDS0101 for HPV16-positive cancers.
The company has no approved products and no product revenue. It posted a net loss of about $7.3 million in the first quarter of 2026 and held roughly $21.7 million in cash as of March 31, 2026. Investors track PDSB mainly for clinical readouts and financing news, which have driven big price swings in the past. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days Versus the Quarter
Over the past 30 days, PDSB moved from a close of about $1.52 on October 12 to roughly $1.00, a decline of around 34%. The stock touched an intraday high near $1.60 in mid-October before giving back most of those gains through late October and early November.
The quarterly view looks quite different. After a strategic reset in mid-August sent shares down to about $0.26, the stock climbed on new financing and clinical data, rising roughly 290% to current levels near $1.00. The recent 34% pullback has therefore retraced only part of a much larger quarterly gain, highlighting the stock’s extreme volatility. One thing that stands out is how quickly sentiment can shift in names like this.
What Drove the Recent 30-Day Decline
The last 30 days reflect a reversal after the strong September–October advance. Following the September PIPE announcement, PDSB surged from around $0.22 in early September to over $1.00 in weeks, helped by a small float and high retail volume. As momentum eased, profit-taking and position unwinding pushed prices lower.
Dilution concerns have added pressure. The financing announced on September 8, 2026, led by Nant Capital with existing investors, aimed to raise up to $22.55 million, with an initial close expected to bring in about $11.55 million. It involved roughly 20.9 million shares or pre-funded warrants plus about 20.4 million common warrants at $0.2825 per unit—well below the October peak. This increase in share count and the warrant overhang have weighed on sentiment as the rally cooled. I’m watching this closely because the low-priced warrants could continue to influence trading.
In addition, PDSB has been trading near the Nasdaq Capital Market’s $1.00 minimum bid price, introducing listing-related uncertainty. With no near-term revenue, the stock stays sensitive to limited news flow.
Quarterly Drivers Behind the Strong Recovery
The main event of the quarter was the company’s strategic refocus. In mid-August, PDS Biotech announced a realignment around its lead asset PDS0301, along with workforce reductions and leadership changes. Shares dropped sharply to about $0.26 as investors digested the shift away from the VERSATILE-003 Phase 3 program for PDS0101.
Recovery started in early September with the PIPE financing led by Dr. Patrick Soon-Shiong of NantWorks. The capital is intended to advance PDS0301 into later-stage trials, backed by interim Phase 2 data in metastatic colorectal cancer. Positive published results from VERSATILE-002 in HPV16-positive head and neck cancer and PDS01ADC data in colorectal and prostate cancer helped support the rebound narrative and the multi-fold quarterly gain.
What to Watch Next for PDSB
Looking forward, key items include the timing of upcoming financial results and updates on cash runway, given the modest cash position reported earlier in 2026. Investors should also track the milestone closing of the PIPE, which depends on submitting a registrational Phase 3 protocol for PDS0301 to the FDA, plus additional colorectal cancer data expected by year-end.
Clinical and regulatory progress on PDS0301, any restart of enrollment in the amended VERSATILE-003 trial, and updates on the PDS0101 licensing option granted to NantWorks will draw attention. Competition from other late-stage programs in the HPV16 head and neck space, including BNTX, and the need to stay above the $1.00 Nasdaq threshold remain important risks. In my view, PDSB’s path depends heavily on clinical data, financing, and regulatory milestones rather than near-term earnings.
Using Tickeron’s AI Tools for Biotech Research
When I analyze volatile names like PDSB, I often turn to Tickeron’s AI Trading Bots to see how automated strategies are positioning across momentum and trend approaches. The platform offers a range of bots that monitor thousands of tickers and surface top performers in real time, which helps me cross-check my own observations without replacing fundamental review. It’s a practical addition to the research process for catalyst-driven stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
PDSB's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 73 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement